Exploring the role of purinergic receptor P2RY1 in type 2 diabetes risk and pathophysiology: Insights from human functional genomics

• Main Authors: Arnaud Dance (Author), Justine Fernandes (Author), Bénédicte Toussaint (Author), Emmanuel Vaillant (Author), Raphaël Boutry (Author), Morgane Baron (Author), Hélène Loiselle (Author), Beverley Balkau (Author), Guillaume Charpentier (Author), Sylvia Franc (Author), Mark Ibberson (Author), Michel Marre (Author), Marie Gernay (Author), Marjorie Fadeur (Author), Nicolas Paquot (Author), Martine Vaxillaire (Author), Mathilde Boissel (Author), Souhila Amanzougarene (Author), Mehdi Derhourhi (Author), Amna Khamis (Author), Philippe Froguel (Author), Amélie Bonnefond (Author)
• Format: Book
• Published: Elsevier, 2024-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2212-8778; 10.1016/j.molmet.2023.101867
• Keywords: Internal medicine; RC31-1245
• Source: Molecular Metabolism, Vol 79, Iss , Pp 101867- (2024)

Objective: Human functional genomics has proven powerful in discovering drug targets for common metabolic disorders. Through this approach, we investigated the involvement of the purinergic receptor P2RY1 in type 2 diabetes (T2D). Methods: P2RY1 was sequenced in 9,266 participants including 4,177 patients with T2D. In vitro analyses were then performed to assess the functional effect of each variant. Expression quantitative trait loci (eQTL) analysis was performed in pancreatic islets from 103 pancreatectomized individuals. The effect of P2RY1 on glucose-stimulated insulin secretion was finally assessed in human pancreatic beta cells (EndoCβH5), and RNA sequencing was performed on these cells. Results: Sequencing P2YR1 in 9,266 participants revealed 22 rare variants, seven of which were loss-of-function according to our in vitro analyses. Carriers, except one, exhibited impaired glucose control. Our eQTL analysis of human islets identified P2RY1 variants, in a beta-cell enhancer, linked to increased P2RY1 expression and reduced T2D risk, contrasting with variants located in a silent region associated with decreased P2RY1 expression and increased T2D risk. Additionally, a P2RY1-specific agonist increased insulin secretion upon glucose stimulation, while the antagonist led to decreased insulin secretion. RNA-seq highlighted TXNIP as one of the main transcriptomic markers of insulin secretion triggered by P2RY1 agonist. Conclusion: Our findings suggest that P2RY1 inherited or acquired dysfunction increases T2D risk and that P2RY1 activation stimulates insulin secretion. Selective P2RY1 agonists, impermeable to the blood-brain barrier, could serve as potential insulin secretagogues.